NEW YORK, NY--(Marketwire - Nov 4, 2011) - [ www.shinesrooms.com ] has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Diagnostic Substances industry and are offering free analytical research on Raptor Pharmaceuticals Corp. (NASDAQ: [ RPTP ]) and IDEXX Laboratories Inc. (NASDAQ: [ IDXX ]). Register with us today at [ http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index.com ] to have free access to these research reports.

Companies within the diagnostic substances industry have not been immune to market woes and fluctuations, but some appear well positioned for short- and long-term growth. Get your free reports on Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. at [ http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index ]. There is no commitment to join.

[ www.shinesrooms.com ] is the Ultimate Trading Environment for investors. If you are considering owning Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. then you should sign up for a free membership and our complimentary reports today at [ www.shinesrooms.com ]. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

On the animal product side of the industry, IDEXX Laboratories has performed well of late. The company's third quarter earnings rose 11%, on the backing of better sales from its animal group business and favorable foreign currency exchange rates. IDEXX Laboratories Inc. report is accessible for free by registering today at [ http://www.shinesrooms.com/IDEXXLaboratoriesInc041111.pdf ].

Companies that operate in smaller niche markets within the diagnostics industry generally rely on quality over quantity. Competition is limited and margins are typically higher, but patient populations are much smaller. As a result, successfully getting treatments to market becomes increasingly important.

Investors may want to track the status of Raptor Pharmaceutical Corp.'s planned NDA submission for DR Cysteamine for the treatment of nephropathiccystinosis. The submission is expected in the first quarter of 2012 and if successful, could lead to long-term gains for the company. Raptor Pharmaceuticals Corp. report is accessible for free by registering today at [ http://www.shinesrooms.com/RaptorPharmaceuticalsCorp041111.pdf ].

The two Diagnostic Substances stocks research reports are available for free by signing up now on [ www.shinesrooms.com ].

About Shinesrooms.com

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link [ http://www.shinesrooms.com/disclaimer.html ].